Shenzhen Capital Group — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Biohengbioheng.comMar 2021 · $80M
Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases.
BiotechDeep TechHealthtechMedical Devices
Jiangtao Ren(Chief Scientific Officer)Lu Han(Chief Executive Officer)Yajin Ni(Chief Technology Officer)Jan Davidson(Chief Medical Officer)
Co-investorsDecheng CapitalGL VenturesHillhouse Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.